OBJECTIVE: We examined the hypothesis that cystatin C, a novel marker of renal function, is elevated in rheumatoid arthritis (RA) and is associated with inflammation and coronary atherosclerosis. METHODS: We measured serum cystatin C, creatinine, tumor necrosis factor-α and interleukin 6 concentrations, coronary artery calcium score (CACS), and Modified Diet in Renal Disease estimated glomerular filtration rate in 167 patients with RA and 91 controls. RESULTS: Cystatin C was higher in RA patients [median (IQR) 1.16 (0.99-1.35) mg/l] than controls [1.01 (0.90-1.19) mg/l; p < 0.001] and correlated positively with erythrocyte sedimentation rate (p < 0.001), C-reactive protein (p = 0.01), 28-joint Disease Activity Score (p = 0.006), and Framingham risk score (FRS; p = 0.02). Cystatin C was correlated with CACS (p < 0.001) in RA, but this was not significant after adjustment for age, race, sex, and FRS (p = 0.44). CONCLUSION: Cystatin C concentrations are higher in RA than controls and may reflect inflammation and undetected subclinical renal dysfunction. Cystatin C provides information regarding the risk of atherosclerosis in RA, but this is not independent of the information provided by conventional cardiovascular risk factors.
OBJECTIVE: We examined the hypothesis that cystatin C, a novel marker of renal function, is elevated in rheumatoid arthritis (RA) and is associated with inflammation and coronary atherosclerosis. METHODS: We measured serum cystatin C, creatinine, tumor necrosis factor-α and interleukin 6 concentrations, coronary artery calcium score (CACS), and Modified Diet in Renal Disease estimated glomerular filtration rate in 167 patients with RA and 91 controls. RESULTS:Cystatin C was higher in RApatients [median (IQR) 1.16 (0.99-1.35) mg/l] than controls [1.01 (0.90-1.19) mg/l; p < 0.001] and correlated positively with erythrocyte sedimentation rate (p < 0.001), C-reactive protein (p = 0.01), 28-joint Disease Activity Score (p = 0.006), and Framingham risk score (FRS; p = 0.02). Cystatin C was correlated with CACS (p < 0.001) in RA, but this was not significant after adjustment for age, race, sex, and FRS (p = 0.44). CONCLUSION:Cystatin C concentrations are higher in RA than controls and may reflect inflammation and undetected subclinical renal dysfunction. Cystatin C provides information regarding the risk of atherosclerosis in RA, but this is not independent of the information provided by conventional cardiovascular risk factors.
Authors: Cecilia P Chung; Annette Oeser; Paolo Raggi; Tebeb Gebretsadik; Ayumi K Shintani; Tuulikki Sokka; Theodore Pincus; Ingrid Avalos; C Michael Stein Journal: Arthritis Rheum Date: 2005-10
Authors: C R Keller; M C Odden; L F Fried; A B Newman; S Angleman; C A Green; S R Cummings; T B Harris; M G Shlipak Journal: Kidney Int Date: 2006-12-20 Impact factor: 10.612
Authors: Michael G Shlipak; Mark J Sarnak; Ronit Katz; Linda F Fried; Stephen L Seliger; Anne B Newman; David S Siscovick; Catherine Stehman-Breen Journal: N Engl J Med Date: 2005-05-19 Impact factor: 91.245
Authors: Cecilia P Chung; Annette Oeser; Joseph F Solus; Ingrid Avalos; Tebeb Gebretsadik; Ayumi Shintani; Paolo Raggi; Tuulikki Sokka; Theodore Pincus; C Michael Stein Journal: Atherosclerosis Date: 2007-01-30 Impact factor: 5.162
Authors: Eric L Knight; Jacobien C Verhave; Donna Spiegelman; Hans L Hillege; Dick de Zeeuw; Gary C Curhan; Paul E de Jong Journal: Kidney Int Date: 2004-04 Impact factor: 10.612
Authors: Nisha I Parikh; Shih-Jen Hwang; Martin G Larson; Udo Hoffmann; Daniel Levy; James B Meigs; Christopher J O'Donnell; Caroline S Fox Journal: Am J Cardiol Date: 2008-05-22 Impact factor: 2.778
Authors: Rossini Botev; Jean-Pierre Mallié; Cecilé Couchoud; Otto Schück; Jean-Pierre Fauvel; Jack F M Wetzels; Nelson Lee; Natale G De Santo; Massimo Cirillo Journal: Clin J Am Soc Nephrol Date: 2009-04-30 Impact factor: 8.237
Authors: Joachim H Ix; Ronit Katz; Bryan Kestenbaum; Linda F Fried; Holly Kramer; Catherine Stehman-Breen; Michael G Shlipak Journal: J Am Soc Nephrol Date: 2008-01-30 Impact factor: 10.121
Authors: Nisha I Parikh; Shih-Jen Hwang; Qiong Yang; Martin G Larson; Chao-Yu Guo; Sander J Robins; Patrice Sutherland; Emelia J Benjamin; Daniel Levy; Caroline S Fox Journal: Am J Cardiol Date: 2008-09-12 Impact factor: 2.778
Authors: R Lertnawapan; A Bian; Y H Rho; P Raggi; A Oeser; J F Solus; T Gebretsadik; A Shintani; C M Stein Journal: Lupus Date: 2011-11-09 Impact factor: 2.911
Authors: Patricia Garcia-Garcia; Raquel Castejon; Pablo Tutor-Ureta; R A Silvestre; Susana Mellor-Pita; Carlos Jimenez-Ortiz; Miguel Yebra-Bango Journal: Clin Rheumatol Date: 2017-09-15 Impact factor: 2.980
Authors: Rachel H Mackey; Lewis H Kuller; Kevin D Deane; Brian T Walitt; Yue-Fang Chang; V Michael Holers; William H Robinson; Russell P Tracy; Mark A Hlatky; Charles B Eaton; Simin Liu; Matthew S Freiberg; Mehret Birru Talabi; Erik B Schelbert; Larry W Moreland Journal: Arthritis Rheumatol Date: 2015-09 Impact factor: 10.995
Authors: Thomas Clark Powell; John P Donnelly; Orlando M Gutiérrez; Russell L Griffin; Monika M Safford; Henry E Wang Journal: BMC Nephrol Date: 2015-04-23 Impact factor: 2.388